Although FIDELIO-DKD and FIGARO-DKD only involved people with diabetes, we believe that MR activation and the associated inflammation and fibrosis may also be relevant in the pathogenesis of nondiabetic kidney disease, and MR antagonism may be an effective therapeutic option in these patients [101]. Here, NR3C2 is linked to diabetic kidney disease.